Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Phase 1CompletedNCT00207077

Eli Lilly and Company33 enrolled

Overview

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Neoplasms

Interventions

Cetuximab + ErlotinibDRUG

IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Measurable disease * Life expectancy of at least 3 months * Must have at least one prior chemotherapy containing a platinum Exclusion Criteria: * Known or documented brain metastases * Prior cetuximab therapy

Locations (1)

Christiana Care Health Services, Inc.

Newark, Delaware, United States

Outcomes

Primary Outcomes

Safety and efficacy of the combination of Tarceva and Erbitux

Secondary Outcomes

Radiographic response

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.